These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
Pharma bad boy Martin Shkreli kept his smirky mouth mostly shut during a court appearance Monday, but then he unloaded once he left the courthouse, where a judge delayed the scheduling of his trial.
"It went great, the judge bitch-slapped the government, again," Shkreli said, bragging to several customers at a Manhattan Dunkin' Donuts where he was live-streaming his coffee purchase on Periscope.
Shkreli continued to stream the rest of his trip back to his apartment. At one point, he said "90 percent of you watching this are morons, maybe not 90 percent, 50 percent."
At Brooklyn federal court Monday, Shkreli pleaded not guilty to a new criminal charge, filed Friday, that alleges a conspiracy to commit securities fraud in the unrestricted securities of his former pharmaceutical company Retrophin.
Shkreli's former attorney, Evan Greebel, is a co-defendant in the case, and he also pleaded not guilty to the latest charge.
Shkreli, 33, last was in court May 3, when federal prosecutors and defense lawyers revealed he could be hit with additional criminal charges in the case.
That ended up happening late last Friday, when a grand jury in Brooklyn issued a superseding indictment that, in addition to the original seven of securities fraud and conspiracy counts, added an eighth charge against Shrekli. The new count charges Shkreli and Greebel with conspiracy to commit securities fraud by hiding Shkreli's control of stock, which he had transferred to seven employees.
Shkreli has said he is innocent of the criminal case, in which prosecutors claim he looted his former pharma company Retrophin for about $11 million to pay off investors he was suspected of previously defrauding in a hedge fund he ran. Retrophin's board ousted Shkreli in 2014, and later sued him for $65 million in connection with his alleged plundering of the company.
At Monday's hearing, in a crowded courtroom, the defense objected to setting the trial date because there are a number of documents they are still waiting to receive from the government, and they also wanted more time to digest the superseding indictment.
Greebel's attorney, Lisa Rubin, said more than 3 million documents needed to be reviewed in the case. Also, she said, the new charge changes the tenor of the case, with respect to Greebel, who previously only faced a single criminal count.
Ben Brafman, Shkreli's lawyer, also argued against setting a trial date. "We're not looking to delay the process, we're looking to be informed by the process," he said.
Brafman also suggested there might be another reason why it could take a while before a trial could be scheduled. He might request that Shkreli be tried separately from Greebel because Shkreli's defense could hinge on "reliance of counsel," which would mean that Shkreli was acting on his attorney's advice.
However, Assistant U.S. Attorney Winston Paes said he didn't think the new charge changed the nature of the case in a material way, and thought a trial date should be set.
"That is the conduct that was also alleged in Retrophin's civil case," Paes said. "So there's no new evidence."
U.S. District Judge Kiyo Matsumoto ended up giving the defense what they were asking for by ordering the defendants back to court on July 14, with the hope of setting up a calendar of motions and possibly setting a trial date. Matsumoto suggested that a trial could be set for some time early next year.
Shkreli gained notoriety last year after raising the price of a drug used to treat toxoplasmosis by more than 5,500 percent as CEO of Turing Pharmaceuticals, the company that he founded after Retrophin's board ousted him. The price of Daraprim jumped from $13.50 per pill to $750 per pill.
Although the price hike drew widespread outrage, it had nothing to do with the criminal charges that were subsequently lodged against him.
In February, investigating drug price increases, citing his Fifth Amendment right against self-incrimination